Please use this identifier to cite or link to this item:
Title: Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males.
Authors: Goldstone, Stephen
Jessen, Heiko
Palefsky, Joel M
Giuliano, Anna R
Moreira Júnior, Edson Duarte
Vardas, Eftyhia
Aranda, Carlos
Hillman, Richard J
Ferris, Daron G
Coutlee, Francois
Marshall, J. Brooke
Vuocolo, Scott
Haupt, Richard M
Guris, Dalya
Garner, Elizabeth I. O
Affilliation: GarnerlaIcahn School of Medicine at Mount Sinai. New York, NY
J2: Private Clinic for Infectious Diseases. Berlin, Germany
University of California San Francisco. Department of Medicine. San Francisco, CA, USA
Risk Assessment, Detection, and Intervention Program. H. Lee Moffitt Cancer Center and Research Institute. Tampa, FL, USA
Associação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil
University of Stellenbosch. Division of Medical Virology. Tygerberg, South Africa / Lancet Laboratories. Johannesburg, South Africah
University Medical Center. National Public Health Institute. Morelos, Mexico
Western Sydney Sexual Health Center. Sydney, Australia
Gynecologic Cancer Prevention Center. Georgia Health Sciences University. Augusta, GA, USA
Université de Montréal. Centre de Recherche du CHUM. Montréal, Quebec, Canada
Merck & Co. North Wales, PA, USA
Merck & Co. North Wales, PA, USA
Merck & Co. North Wales, PA, USA
Abstract: A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term
Keywords: HPV
Men who have sex with mena
DeCS: Neoplasias do Ânus/virologia
Infecções por Papillomavirus/prevenção & controle
Infecções por Papillomavirus/virologia
Vacinas contra Papillomavirus/uso terapêutico
Canal Anal/patologia
Neoplasias do Ânus/epidemiologia
Neoplasias dos Genitais Masculinos/patologia
Papillomavirus Humano 11/patogenicidade
Papillomavirus Humano 16/patogenicidade
Infecções por Papillomavirus/epidemiologia
Resultado do Tratamento
Adulto Jovem
Issue Date: 2013
Publisher: Elsevier Ltd
Citation: GOLDSTONE, S. E. et al. Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine, v. 31, n. 37, p. 3849-3855, 2013.
ISSN: 1873-2518
Copyright: open access
Appears in Collections:BA - IGM - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Goldstone SE Quadrivalent....pdf672.28 kBAdobe PDFView/Open

FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.